Back to today’s briefing

Story perspectives

NIH and FDA Clash Over AI's Future in Healthcare

6/11/2025

40 6

Summary

Story summary

The NIH and FDA are navigating the evolving landscape of AI in healthcare with distinct strategies. While the NIH champions AI research, the FDA prioritizes regulatory oversight. Their recent launch of "Elsa," an AI tool aimed at boosting employee efficiency, has sparked concerns over its limitations and biases, fueling ongoing debates about AI's future in medicine.

1 of 1

Story summary

The NIH and FDA are navigating the evolving landscape of AI in healthcare with distinct strategies. While the NIH champions AI research, the FDA prioritizes regulatory oversight. Their recent launch of "Elsa," an AI tool aimed at boosting employee efficiency, has sparked concerns over its limitations and biases, fueling ongoing debates about AI's future in medicine.